the inherent properties of the malignant cells, and by the properties of tumor stroma and unidentified factors [10] . In spite of developments in OSCC treatment, recurrence and mortality rates are continuously increasing in patients with bone invasion [11] .
To promote the quality of life and survival, it is necessary to improve diagnosis and therapy for OSCC patients with bone invasion based on molecular mechanisms by which OSCC invades bone. Therefore, we will focus on critical molecular markers associated with bone invasion by OSCC.
Proteases
Bone tissue consists of several distinct cell types and a mostly mineralized bone matrix. Osteocytes are integrated within bone and participate in the bone remodeling process with various cell types, including osteoprogenitor cells, osteoclasts, osteoblasts, marrow fibroblasts, and undifferentiated cells [12, 13] . Bone-tropic tumor cells produce a variety of enzymes to directly destroy extracellular matrix (ECM) and then migrate into the surrounding tissues [14] . In addition, tumor-derived proteolytic enzymes stimulate differentiation and maturation of bone cells, especially osteoclast precursors, resulting in osteolysis. Matrix metalloproteinases (MMPs) and cathepsins have been considered pivotal proteases in OSCCmediated bone invasion.
MMPs are the proteolytic enzymes responsible for degradation of fibrillar and non-fibrillar collagens, gelatin, elastin, and proteoglycans. Some MMPs are detected at high levels in cartilage and bone of mammals, including humans and mice, and are able to cleave native, non-denatured collagens by potentially functioning as collagenases in vivo [15] . MMP-1 and MMP-9 were strongly expressed in highly differentiated BHY OSCC cells [16] . In another study, 9 of the 24 buccal SCC with mandibular invasion were intensely stained for active MMP-7 but not 15 without bone invasion, representing that MMP-7 is connected with mandibular invasion [17] . MMP-7 secreted from breast and prostate cancer cells cleaved the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) to its active soluble form, which triggers osteoclast differentiation and bone resorption [18, 19] . In addition, high expression of MMP-9 is detected in the cytoplasm of invading OSCC cells [20] .
Cathepsins are lysosomal proteases that degrade proteins at acidic pH. In normal cells, cathepsins modulate the immune responses and signaling pathways. Abnormal cathepsin activity is commonly implicated for altered immunologic and physiological behavior that is caused by cancers [21, 22] . Cathepsins, including cathepsin D, E, K, and L, play a crucial role in bone resorption by osteoclasts [23] . Procathepsin L was secreted from BHY cells in large amounts and the active cathepsin L degraded the demineralized bone matrix [24] . The injected BHY cells on the masseter muscle of nude mice developed into highly differentiated SCC invading the mandible, demonstrating that cathepsin L might support to degrade the bone matrix [24] . Cathepsin B and D were intensely expressed in all 78 SCC of tongue, gingiva, or floor of mouth and the labeling indices of the two cathepsins were closely correlated with the degree of bone invasion [25] . Furthermore, the survival period in patients with high serum levels of cathepsin B and D was short, indicating that these molecules could be useful as prognostic indicators.
Cytokines
Osteoclasts are actually hematopoietic cells, originated from the macrophage/monocyte lineage. The differentiated osteoclasts attach to the bone matrix and then secrete protons to resorb inorganic components and soluble enzymes to degrade organic components of bone matrix [26] . Two hematopoietic factors are required for differentiation of osteoclast precursors to mature osteoclasts (osteoclastogenesis): RANKL and macrophage colony-stimulating factor (M-CSF). Tumor necrosis factor (TNF) receptor/TNF-like proteins, including RANKL, its receptor RANK, and osteoprotegerin (OPG), regulate osteoclast differentiation [27] . RANKL functions a key inducer of bone resorption by binding to RANK but OPG acts as a soluble decoy receptor [28] . Osteoclastogenesis and activation of boneresorbing osteoclasts appears to be the most important factor in OSCC bone invasion [29, 30] . In OSCC-induced bone invasion, tumor-derived cytokines, including TNF-α, can directly or indirectly induce osteoclast formation by stimulating RANKL or M-CSF expression [3, 31] .
Interleukins (ILs), a family of pleiotropic cytokines derived from osteoblasts, osteoclasts, and stromal cells, play an important role in controlling the metabolism of bone [12] . Osteoclasts share many regulatory molecules with immune cells, thereby several immune cells differentiate as the osteoclasts in bone microenvironment [32] . The discovery that cultured human peripheral blood leukocytes can absorb bone supports the connection between immune system and bone metabolism [33] . IL-1b has been recognized as a primary mediator [34] but IL-6, IL-11, and IL-15 as well promote bone resorption [35] . Parathyroid hormone-related peptide (PTHrP), another key molecule of bone homeostasis, plays a role in preventing apoptosis of osteoblasts and recruiting osteoclasts, and is upregulated in the tissues of OSCC patients [36] . The binding of PTHrP to its receptors stimulates osteoclast activity and facilitates bone destruction [37] . [39] . Additionally, chemokines produced by tumor cells regulate recruitment and mobilization of osteoclasts [40] .
CXCL13 and its receptor CXCR5 promoted RANKL expression in OSCC cells and prevented bone invasion by OSCC through
NFATc3 and c-Myc expression [41] [42] [43] . CXCL2 was found to be involved in bone destruction by expressing RANKL [44] .
Growth Factors
Many growth factors influence function of osteoblasts and osteoclasts during bone remodeling. In the progression of the OSCC, osclast-mediated bone resorption induces secretion of growth factors from reservoirs within mineralized bone matrix, including transforming growth factor (TGF), epidermal growth factor, or connective tissue growth factor, which function as local managers of tumor growth and bone destruction [45] .
Various growth factors advance the local microenvironment around tumor cells that express receptors for growth factors, promote tumor cell proliferation, and suppress their apoptosis [46] [47] [48] . TGF-b1 not only induces epithelial-mesenchymal transition to increase OSCC invasion capacity but also upregulates factors for prolonged osteoclast survival [49] . Recent studies have shown that TGF-b1 overexpression promoted invasiveness, migration, and angiogenesis of SCC9 cells by activating slug/MMP-9 axis [50] .
Conclusions
OSCC bone invasion is an extremely coordinated process that can described in 'vicious cycle' of early, resorption, and ultimate stages, which is stimulated by interaction between OSCC cells, osteoblasts, osteoclasts, and bone matrix-derived factors (Fig. 2) . In the early stage, proteases degrade the ECM of the adjacent soft tissues and promote the invasion of OSCC into the bone. The next step in bone invasion is the resorption stage, where osteoclasts play a major role in absorbing the mineral components of the bone. Osteoclast-mediated resorption leads to ultimate stage of bone invasion by secreting growth factors from bone matrix and consequently exacerbate OSCC bone invasion by promoting the growth of tumor cells.
Previous studies have reported molecular mechanisms associated with OSCC invasion, based on OSCC characteristics. Although many researchers are exploring molecular mechanisms of OSCC bone invasion, novel targeted markers are still needed to quickly predict bone invasion and to treat patients. The useful target molecules that can predict and serve to treat OSCC bone invasion will increase early diagnostic and therapeutic success and effectively reduce the morbidity and mortality associated with bone invasion by OSCC.
